logo-loader
viewMotif Bio PLC

Motif Bio celebrates 'major milestone' in antibiotic trial'

Motif Bio Plc (LON:MTFB) has passed a major landmark after treating the final patient taking part in the first of two phase III clinical trials of its next-generation antibiotic, iclaprim.

Chief executive Graham Lumsden tells Proactive: ''This was a major milestone for us to be able to announce that we've finally completed the treatment phase for all 600 patients in this REVIVE-1 trial''.

Successful completion of the two final-stage trials should pave the way for regulatory submissions ahead of the formal green light of the drug in the US and Europe for patients with acute bacterial skin and skin structure infections (ABSSSI).

Quick facts: Motif Bio PLC

Price: 0.0576 GBX

AIM:MTFB
Market: AIM
Market Cap: £279.56 k
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Enthusiasm of Belvoir Group franchisees during crisis has been incredible...

Dorian Gonsalves, chief executive of Belvoir Group PLC, says the company’s franchisees will be ready to go straight out and start letting again as soon as the lockdown is lifted. Belvoir is actively transacting business on all sides except estate agency, where transactions have all but...

4 hours, 54 minutes ago

2 min read